Effects of chia seeds on blood cholesterol and triglyceride levels

Effects of CHIA SEED based nutraceutical products on LIPID metabolism in healthy subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16949080

Enrollment

150

Registered

2017-02-21

Start date

2017-02-16

Completion date

Unknown

Last updated

2017-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome (MeTS) Nutritional, Metabolic, Endocrine Metabolic Syndrome (MeTS)

Interventions

Participants are asked to fill out a food frequency questionnaire at the beginning of the study. Participants in all groups eat a placebo daily for one month. Participants are then randomly allocated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-83 years old 2. Caucasian 3. Have the following range values of serum cholesterol parameters at baseline: 3.1. TC, 200-260 mg/dL 3.2. HDL-C, 31-45 mg/dL 3.3. LDL-C, 190-205 mg/dL 3.4. TG, 170-280 mg/dL 4. Body mass index (BMI) between 18 and 30 kg/m2

Exclusion criteria

Exclusion criteria: 1. Smoking 2. Obesity (BMI >30 kg/m2) 3. Diabetes 4. Hepatic disease 5. Renal disease 6. Heart disease 7. Family history of chronic diseases 8. Drug therapy or supplement intake for hypercholesterolemia 9. Drug therapy or supplement intake containing apple polyphenols 10. Heavy physical exercise (more than10 hours per week) 11. Pregnant women, women suspected of being pregnant, women who hoped to become pregnant, breastfeeding 12. Birch pollen allergy 13. Use of vitamin/mineral supplements 2 weeks prior to entry into the study 14. Donation of blood less than 3 months before the study

Design outcomes

Primary

Measure	Time frame
1. Plasma TC is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks 2. HDL-C is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks 3. LDL-C is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks 4. Triglyceride levels are measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks	—

Measure

Time frame

1. Plasma TC is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks 2. HDL-C is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks 3. LDL-C is measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks 4. Triglyceride levels are measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks

—

Secondary

Measure	Time frame
1. Clinical history is measured by interviews and previous clinical data at baseline 2. Anthropometric measures are measured by taking height and weight at baseline, 4, 8, 12 and 16 weeks 3. Nutrient intake and dietary habits are measured using a seven day food record validated nutritional questionnaire at baseline, 4, 8, 12 and 16 weeks 4. Blood pressure is measured using a blood pressure cuff at baseline, 4, 8, 12 and 16 weeks 5. 24 hour ambulatory blood pressure is measured using blood pressure cuff at baseline, 4, 8, 12 and 16 weeks 6. Blood levels (AST, ALT, ?-GTP, ALP, LDH, Albumin, Total bilirubin, Creatinine) are measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks	—

Measure

Time frame

1. Clinical history is measured by interviews and previous clinical data at baseline 2. Anthropometric measures are measured by taking height and weight at baseline, 4, 8, 12 and 16 weeks 3. Nutrient intake and dietary habits are measured using a seven day food record validated nutritional questionnaire at baseline, 4, 8, 12 and 16 weeks 4. Blood pressure is measured using a blood pressure cuff at baseline, 4, 8, 12 and 16 weeks 5. 24 hour ambulatory blood pressure is measured using blood pressure cuff at baseline, 4, 8, 12 and 16 weeks 6. Blood levels (AST, ALT, ?-GTP, ALP, LDH, Albumin, Total bilirubin, Creatinine) are measured using a blood test (analysis by spectrophotometer) at baseline, 4, 8, 12 and 16 weeks

—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026